Skip to main content
. 2020 Aug 27;26(12):2318–2322. doi: 10.1016/j.bbmt.2020.08.025

Table 1.

Patient Characteristics

Characteristic Total Cases (N = 390) Any CT Abnormality (n = 192) No CT Abnormality (n = 198) P Value
Age, median (range) 48 (15-69) 53 (16-69) 45 (15-68) <.001
Sex, No. (%)
 Male 234 (60.0) 114 (59.4) 120 (60.6) .84
 Female 156 (40.0) 78 (40.6) 78 (39.4)
Diagnosis, No. (%)
 AML 164 (42.1) 81 (42.2) 83 (41.9) .16
 ALL 69 (17.7) 34 (17.7) 35 (17.7)
 MDS 57 (14.6) 32 (16.7) 25 (12.6)
 NHL 43 (11.0) 23 (12.0) 20 (10.1)
 MPN 23 (5.9) 8 (4.2) 15 (7.6)
 SAA 15 (3.8) 7 (3.6) 8 (4.0)
 MM 10 (2.6) 1 (0.5) 9 (4.5)
 Other 9 (2.3) 6 (3.1) 3 (1.5)
Disease risk, No. (%)
 Standard 276 (70.8) 129 (67.2) 147 (74.2) .15
 High 114 (29.2) 63 (32.8) 51 (25.8)
HCT-CI, median (range) 0 (0-7) 0 (0-7) 0 (0-7) .0061
Donor type, No. (%)
 Matched sibling 86 (22.1) 32 (16.7) 54 (27.3) .018
 Matched unrelated 168 (43.1) 96 (50.0) 72 (36.4)
 Mismatched sibling 51 (13.1) 28 (14.6) 23 (11.6)
 Mismatched unrelated 58 (14.9) 23 (12.0) 35 (17.7)
 Cord blood 27 (6.9) 13 (6.8) 14 (7.1)
Conditioning, No. (%)
 MAC 241 (61.8) 107 (55.7) 134 (67.7) .017
 RIC 149 (38.2) 85 (44.3) 64 (32.3)
TBI dose, median (range) 4 (0-12) 4 (0-12) 12 (0-12) .0014
Smoking habit, No. (%) 218 (55.9) 120 (62.5) 98 (49.5) .011
HT, No. (%) 58 (14.9) 29 (15.1) 29 (14.6) 1.0
DLP, No. (%) 20 (5.1) 8 (4.2) 12 (6.1) .49
DM, No. (%) 25 (6.4) 12 (6.3) 13 (6.6) 1.0

AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; MPN, myeloproliferative neoplasm; SAA, severe aplastic anemia; MM, multiple myeloma; HCT-CI, hematopoietic cell transplantation comorbidity index; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; HT, hypertension; DLP, dyslipidemia; DM, diabetes mellitus.